Search Results

USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma.

National Distributor to Sell Cold Sore Prevention Device Through National Ecommerce Sales Through Direct to Consumer Marketing Efforts

Panbela Therapeutics, Inc. (Nasdaq: PBLA) today announced that US WorldMeds®1 (USWM), a Kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients who have achieved at least a partial response to certain prior therapies.

Though data became an issue in two separate meetings, the FDA’s Oncologic Drugs Advisory Committee made a potentially precedent-setting decision by voting in favor of US WorldMeds’ neuroblastoma treatment.

Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by President Donald Trump.

DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI® Injection 0.3mg and SYMJEPI® Injection 0.15mg products from USWM, LLC.

Maxwell’s 7th signed US military agreement is for in vitro testing of Maxwell’s Claromers for the treatment of diarrheal pathogens